Myeloma: Pathology, Diagnosis, and Treatment

Overview

Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, ...
See more details below
Other sellers (Hardcover)
  • All (11) from $68.73   
  • New (8) from $92.30   
  • Used (3) from $68.73   
Myeloma: Pathology, Diagnosis, and Treatment

Available on NOOK devices and apps  
  • NOOK Devices
  • Samsung Galaxy Tab 4 NOOK 7.0
  • Samsung Galaxy Tab 4 NOOK 10.1
  • NOOK HD Tablet
  • NOOK HD+ Tablet
  • NOOK eReaders
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook)
$71.99
BN.com price
(Save 30%)$104.00 List Price

Overview

Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman's syndrome, Waldenstrom's macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.
Read More Show Less

Editorial Reviews

Doody's Review Service
Reviewer: Firoozeh Sahebi, M.D.(City of Hope)
Description: This book addresses different aspects of the debilitating disease of myeloma, including epidemiology, biology, pathogenesis, diagnosis, and treatment, and reviews other plasma cell dyscrasia such as POEMS syndrome, Castleman disease, amyloidosis, and Waldenstrom macroglobulinemia.
Purpose: The purpose is to provide a deeper understanding of the disease biology, from cell cycle regulation, signaling pathways, genetic and epigenetic changes to the role of bone marrow microenvironment, with six chapters dedicated to these topics. The book provides a collective understanding of the disease biology and descriptions of carefully designed clinical studies. It reviews the recent advances in the diagnosis and treatment of the disease and provides an important source of information for clinicians and scientists in the field.
Audience: The book is written for healthcare professionals, including physicians, nurse practitioners, scientists, and researchers. The authors are the expert authorities in the field.
Features: The strength of the book is its clear presentation of the existing knowledge of the biology of the disease and diagnosis. The short, well-written chapters include figures, tables, graphs, and imaging studies useful for conceptualizing the information. Treatment strategies are summarized based on pivotal phase II and randomized phase III studies with relevant references. However, two important areas of ongoing research in the treatment of the disease are missing. One is the exciting and accumulating data on the role of minimal residual disease (MRD). Although this is mentioned in the first chapter under diagnosis, its influence in predicting outcome and directing therapeutic decisions in the near future requires an in-depth discussion in the treatment chapter. The second topic is the active research into using new targeted agents and radiation technology (i.e. IMRT) as conditioning regimens in the field of transplantation. These areas of research among many others are important in advancing the field.
Assessment: This is a well-written and well-structured book focused on disease biology, which is the backbone of present and future treatment strategies. It is an important source of information for both clinicians and researchers.
Read More Show Less

Product Details

  • ISBN-13: 9781107010574
  • Publisher: Cambridge University Press
  • Publication date: 11/30/2013
  • Pages: 305
  • Product dimensions: 7.70 (w) x 9.70 (h) x 0.70 (d)

Meet the Author

Stephen A. Schey is Professor of Plasma Cell Dyscrasias, King's College London, and a Consultant Haematologist at King's College Hospital NHS Foundation Trust, London.

Kwee L. Yong is Professor of Clinical Haematology, University College London, and a Consultant Haematologist at University College London Hospitals, London.

Robert Marcus is a Consultant Haematologist at King's College Hospital NHS Foundation Trust, London.

Kenneth C. Anderson is Kraft Family Professor of Medicine, Harvard Medical School, and Medical Director, Kraft Family Blood Donor Center, Dana-Faber Cancer Institute, Boston.

Read More Show Less

Table of Contents

Preface; Part I. Overview of Myeloma: 1. Epidemiology of myeloma Eve Roman and Alexandra G. Smith; 2. Diagnosis and immunophenotyping of myeloma Roger Owen; 3. Imaging of myeloma Nicola Mulholland and Ming Wan; Part II. Biological Basis for Targeted Therapies in Myeloma: 4. Cell cycle regulation and myeloma precursor cells John Quinn and Kwee L. Yong; 5. The genetic and epigenetic mechanisms underlying the behaviour of myeloma Martin F. Kaiser, Kevin D. Boyd and Gareth J. Morgan; 6. The myeloma bone marrow environment and survival signaling Kwee L. Yong, John Quinn and Asim Khwaja; 7. Immune dysfunction in multiple myeloma Guy Pratt and Paul Moss; 8. Myeloma bone disease: pathogenesis of bone destruction and therapeutic strategies Andrew Chantry and Neil Rabin; 9. Principles of pathway directed therapy for myeloma Yu-Tzu Tai and Kenneth C. Anderson; Part III. Myeloma: Clinical Entities: 10. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma Efstathios Kastritis and Meletios A. Dimopoulos; 11. Multiple myeloma: management of de novo disease T. Guglielmelli, P. Sonneveld, A. Broyl and Antonio Palumbo; 12. Treatment of relapsed/refractory myeloma Matthew J. Streetly, Jacob Laubach, Paul Richardson and Stephen A. Schey; 13. Solitary bone and extramedullary plasmacytoma Shirley D'Sa; 14. Amyloidosis Ashutosh D. Wechalekar, Simon W. Dubrey and Raymond L. Comenzo; 15. Waldenstrom's macroglobulinemia/lymphoplasmocytic lymphoma Steven P. Treon and Giampaolo Merlini; 16. Castleman's disease Karthik Ramasamy; 17. POEMS syndrome and paraproteinaemic syndromes: management and follow-up Angela Dispenzieri and Suzanne R. Hayman; Part IV. Supportive Therapies: 18. Treatment of emergent peripheral neuropathy and plasma cell disorders Charise Gleason, Melanie Watson and Sagar Lonial; 19. Management of renal failure in multiple myeloma Aneel Paulus, Pooja Advani, Nabeel Aslam and Asher Alban Chanan-Khan; 20. The management of infection in myeloma Christopher P. Conlon; Index.
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)